Broad Coverage of Genetically Diverse Strains of Clostridium difficile by Actoxumab and Bezlotoxumab Predicted by <i>In Vitro</i> Neutralization and Epitope Modeling
Lorraine D. Hernandez(Merck & Co., Inc., Rahway, NJ, USA (United States)), Alex G. Therien(Merck Canada Inc. (Canada)), Fred Racine(Merck & Co., Inc., Rahway, NJ, USA (United States)), Nichelle Hairston(Merck & Co., Inc., Rahway, NJ, USA (United States)), Li Xiao(Merck & Co., Inc., Rahway, NJ, USA (United States)), Nicholas Murgolo(Merck & Co., Inc., Rahway, NJ, USA (United States)), Payal R. Sheth(Merck & Co., Inc., Rahway, NJ, USA (United States)), Edward DiNunzio(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 54
Related Papers
Antibiotic Susceptibility Profiles of <i>Escherichia coli</i> Strains Lacking Multidrug Efflux Pump Genes
|Antimicrobial Agents and Chemotherapy|2001|502
Selective small-molecule inhibition of an RNA structural element
|Nature|2015|419
Targeted deletion of Gpbar1 protects mice from cholesterol gallstone formation
|Biochemical Journal|2006|272